Hoth Therapeutics Business Summary

Hoth Therapeutics, Inc. (HOTH) is a clinical-stage biopharmaceutical company that operates on a pre-revenue business model, currently generating capital through public equity offerings, debt financing, and strategic research grants. The company’s primary business segments are organized around its therapeutic pipeline, which targets high-need areas including oncology supportive care (HT-001 for EGFR-inhibitor associated rashes), mast cell-driven cancers (HT-KIT), neuroinflammatory diseases (HT-ALZ for Alzheimer’s), and metabolic disorders (GDNF for obesity). As of early 2026, Hoth is focused on advancing its lead assets through Phase 2 trials and IND-enabling studies, with a long-term revenue strategy centered on the potential licensing of its proprietary intellectual property to larger pharmaceutical partners or the commercialization of its specialized drug formulations. Direct competitors include iBio, Inc. (IBIO), Precision BioSciences (DTIL), MIRA Pharmaceuticals (MIRA), and Lipocine Inc. (LPCN); Hoth distinguishes itself within this small-cap peer group by maintaining a highly diversified, multi-indication pipeline that leverages both novel biologics and repurposed therapeutic platforms to address niche unmet medical needs. Hoth’s leadership team is led by Founder, President, and CEO Robb Knie, who also serves as Chairman of the Board and brings over 20 years of equity market experience, including a background as a semiconductor and independent equity analyst. The executive suite includes Chief Financial Officer David Briones, who oversees the company’s capital management and SEC reporting, and Chief Scientific Officer Stefanie Johns, Ph.D., a protein biochemistry expert who leads the clinical and regulatory strategy for the pipeline. Operations are managed by Hayley Springer, Executive Vice President of Operations. The company’s Board of Directors features a blend of legal and medical expertise, including David Sarnoff, a veteran in executive leadership coaching, and Dr. Jeff Pavell, Chief of Rehabilitation Medicine at Englewood Health. Notable institutional backing has historically included positions from Citadel Advisors, Armistice Capital, and Virtu Financial, reflecting a shareholder base comprised of specialized healthcare hedge funds and major institutional asset managers.